KKR Real Estate Finance Trust NYSE: KREF reported a GAAP net loss of $62 million, or negative $0.96 per share, for the first quarter of 2026, as management emphasized that the year is expected to be a “transition year” focused on resolving watchlist assets, reducing certain legacy exposures, and positioning parts of its real estate owned (REO) portfolio for liquidity.
Director Jack Switala said book value was $11.87 per share as of March 31, 2026. The company posted a distributable loss of $4 million, or negative $0.06 per share, while distributable earnings before realized losses totaled $13 million, or $0.20 per share. The company paid a $0.25 cash dividend in April with respect to the first quarter.
Management outlines 2026 “transition year” priorities
CEO Matt Salem said management is focused on narrowing the gap between the company’s share price and book value per share through two main priorities: “executing an aggressive resolution strategy across our watchlist assets and certain legacy office exposures” and “positioning a portion of our REO portfolio for liquidity.”
Salem said book value declined 9% during the quarter as the company positions watchlist loans for resolution, adding that management “may choose to incur book value declines as we seek liquidity on legacy assets to create a higher-quality portfolio.” He said the company sees a path to redeploy capital into “newer vintage, higher-quality investments,” with the aim of returning to book value stability over time.
Among the 2026 objectives Salem outlined:
- Reduce legacy office exposure from 21% to under 10%, with more than half expected to come from par repayments and the remainder from watchlist resolutions.
- Resolve all current watchlist loans by year-end through sale positioning, modifications, and other accelerated resolutions.
- Modify 100% of life science exposure; Salem said 19% had been modified, rising to 30% when including the company’s Cambridge asset this quarter. He also noted a “material increase in reserves” for the Seaport loan “in anticipation of a potential modification.”
- Rotate the portfolio into newer-vintage originations, with 2024-2026 originations expected to represent about 50% of the portfolio by year-end.
Salem highlighted one early step in lowering office exposure: the company’s largest office loan, a $225 million loan in Bellevue, was refinanced at par in the first quarter using a CMBS single-asset, single-borrower transaction. He also said the property securing the company’s largest watchlist office loan is being marketed for sale.
Dividend cut and a new $75 million repurchase authorization
Salem said the company reduced its dividend to $0.10 per share per quarter, payable July 15. He emphasized the decision “is not driven by liquidity constraints,” noting the company had $653 million of liquidity and expected more than $2 billion of repayments in 2026, which management expects to translate into more than $500 million of capital to invest.
Instead, Salem framed the cut as capital allocation. “At this stage, we see more attractive opportunities, including repurchasing our stock and funding new originations,” he said, adding that the new dividend level aligns with expectations for distributable earnings per share before realized losses while the portfolio is being repositioned.
Salem said quarterly results may vary in the near term, with earnings expected to “trough in the second half of 2026 into the first half of 2027,” followed by an expected increase in distributable earnings per share once the company moves through that period.
On April 14, the board authorized a new $75 million share repurchase program. Salem said the company had been “largely inactive” on buybacks during the quarter due to trading restrictions while evaluating dividend policy, but those constraints have been lifted following the decision.
Watchlist movement and CECL provisions
President and COO Patrick Mattson said the company downgraded its Philadelphia office assets and two smaller Texas multifamily loans from risk-rated 3 to 4. He also said the company downgraded a Boston life science asset from risk-rated 3 to 5, while upgrading its Cambridge life science exposure from risk-rated 5 to 3 following a restructuring that included new sponsor equity and a loan paydown.
Mattson said the company recorded CECL provisions of $74 million in the quarter, bringing its total allowance to $260 million.
During the Q&A, Salem said the company’s goal is to “monetize the vast majority” of watchlist assets, using a mix of modifications and note sales, and reiterated a goal to clear the watchlist by year-end. On the two Texas multifamily loans, Salem said they were downgraded because sale prices could be close to the debt as the sponsors sell the properties, potentially leading to small losses. He added the company does not view those loans as indicative of broader multifamily credit issues, saying KREF does not expect “material losses” across its multifamily loan portfolio.
KBW analyst Jade Rahmani asked about risk migration, and Salem said the typical progression is from risk 3 to 4 to 5, noting that “in the vast majority of cases, that’s what’s happened,” while acknowledging there can be “jump risk” around maturities or modification discussions.
REO monetization roadmap and Mountain View lease
Mattson said the REO portfolio is being managed with a focus on monetization and grouped into near-, medium-, and longer-term buckets.
- Near-term: West Hollywood condos (units listed and closings returning equity), Raleigh, North Carolina multifamily (upgrades underway with a sale listing expected by year-end), and a Philadelphia office asset (about 85% leased, with plans to sell this year).
- Medium-term: Mountain View, California office (a long-term lease was signed with OpenAI, and the company expects to bring the asset to market within 12 to 16 months), and a Portland redevelopment (near final entitlement on over 4 million square feet of mixed-use space, with monetization expected to begin over the course of the year).
- Longer-term: Seattle life science (focus on leasing and stabilization), and Boston life science (currently a risk-rated 5 loan expected to transition to REO in the second quarter).
On the Boston life science loan expected to move to REO, Mattson said it is expected to result in a realized loss of approximately $37 million, though he said the company is “adequately reserved as of the first quarter.”
Mattson estimated that monetizing REO assets and redeploying capital into new investments could generate “more than $0.15 per share of incremental quarterly earnings over time,” with nearly half attributed to the Mountain View REO asset.
Asked for more detail on the Mountain View lease, Salem said the company is under a “pretty tight NDA,” but described it as a long-term lease the company believes “will trade like a net lease,” potentially broadening the buyer base to net lease investors. Salem also said the company views the asset as potentially accretive to book value following the lease, noting it had been “marked down significantly” prior to having a tenant.
Liquidity, leverage, and origination outlook
Mattson said KREF ended the quarter with $653 million of liquidity, including $135 million in cash and $500 million of undrawn capacity on its corporate revolver, plus over $500 million of unencumbered assets. Total financing availability was $7.2 billion, including $2.6 billion of undrawn capacity, and 77% of financing was non-mark-to-market, he said.
Originations totaled $184 million in the quarter, while repayments were $415 million, with about 75% of repayments driven by legacy office, according to Mattson. He added that in the first three weeks of the second quarter, the company had “already closed or circled over $400 million of new loans.”
Mattson said the company has no final facility maturities until 2027 and no corporate debt due until 2030. He reported a 2.2x debt-to-equity ratio and total leverage of 4x, which he said was consistent with the company’s target range.
In response to BTIG’s Tom Catherwood on the company’s goal for newer-vintage loans to reach about 50% of the portfolio by year-end, Salem said an estimate of roughly $1 billion to $1.2 billion of originations is “certainly in the ballpark,” though he noted it will depend partly on the level of share repurchases. Salem also said the company does not need to time REO sales to hit that newer-vintage target, pointing to expected loan repayments as the primary source of investable capital.
Raymond James’ Gabe Poggi asked about leverage considerations in balancing buybacks and new loans. Salem said the company is “not changing our leverage targets” and wants to remain in its 3.5x to 4x range, adding that repayments provide flexibility. Poggi also asked about potential fee relief from the manager during the transition; Salem said the company is “evaluating everything” and that “all options…are on the table.”
On life science leasing conditions, Salem said the outlook is market dependent. He said South San Francisco has shown improved conditions tied to office demand from AI-related tenants and some early signs of life science companies returning, while Boston is “a little bit behind” San Francisco, though he said tenants are “actively engaged” in the market.
About KKR Real Estate Finance Trust NYSE: KREF
KKR Real Estate Finance Trust, Inc NYSE: KREF is a mortgage real estate investment trust sponsored by KKR & Co Inc The company focuses on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and real estate-related assets across the United States and select European markets.
The trust's investment strategy is centered on lending to high-quality office, industrial, retail, multifamily and hotel properties. Its portfolio primarily consists of senior mortgage loans, mezzanine loans, floating-rate debt securities and preferred equity positions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KKR Real Estate Finance Trust, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KKR Real Estate Finance Trust wasn't on the list.
While KKR Real Estate Finance Trust currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
